Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Loyola University
- Registration Number
- NCT00002474
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 77
- Registration Number
- NCT00045630
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 48
- Registration Number
- NCT00003385
- Locations
- 🇺🇸
MBCCOP - Hawaii, Honolulu, Hawaii, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: isotretinoinDrug: melphalanDrug: topotecan hydrochlorideDrug: vincristine sulfateProcedure: autologous bone marrow transplantationProcedure: bone marrow ablation with stem cell supportProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 495
- Registration Number
- NCT00004188
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 842
- Registration Number
- NCT00021060
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT00025389
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00027898
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00006469
- Locations
- 🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, Maryland, United States
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 92
- Registration Number
- NCT00003612
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00005051
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Saint Vincent Catholic Medical Center of New York, New York, New York, United States
🇺🇸New York Hospital Medical Center of Queens, Fresh Meadows, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.